2023-04-13 10:15:00 ET
Among the growth-heavy stocks of the Nasdaq Composite , a few companies stand out as being especially promising. At the moment, two enterprising biopharma players -- Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) -- are particularly appealing. That's thanks to their combination of relative security and near-term catalysts.
What's more, their fates are intertwined, so an investment in one could benefit from the positive developments of the other. Here's why it's worth buying at least one of the pair.
Image source: Getty Images.
For further details see:
2 Nasdaq Growth Stocks That Are Screaming Buys in April